Fin Cascade

Prices as of 20 Nov 2026 close · Not investment advice

Updated 21 Nov, 20:31 IST

Bio Medica Laboratories Limited

NSE: BMLL · Pharmaceuticals

Share price ₹160.70

up 10.83% · close of 20 Nov 2026

Business scoreHow strong the business is, in one number.Changed 20 Nov 2026How it was built →

Your ratios

Market cap

₹202 Cr

P/E ratio

17.0

EPS FY to Mar 2026

P/B ratio

Pending

₹47 Cr IPO · by 27 May

ROCE

37.5%

ROE

58.0%

Dividend yield

0.0%

as of 20 Nov 2026

Profit checks5/7 clear

1 · Overview

Overview

Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.

Price
Loading BMLL data…

At a glance · Max

Every small chart follows the range above. Point at it to read a value; click it to open it.
Revenue (sales)
₹22.0 Cr
Sep 2026
Mar 2025 – Sep 2026 · 4 quarters
Operating margin
28.0%
average 38.2% · low 28.0% · high 46.0%
Mar 2025 – Sep 2026 · 4 quarters
Net profit
₹3.00 Cr
Sep 2026
Mar 2025 – Sep 2026 · 4 quarters
EPS (yearly)
₹12.95
FY26 · +21.48% on FY25
FY23 – FY26 · 4 years
Promoter holding
67.70%
FII 4.8% · DII 3.6%
May 2026 – Sep 2026 · 2 quarters

2 · Results

Latest result · Q2 FY27

What the last results showed. Whether management kept its word is in Pro.

Net profit ₹3.00 Cr in the quarter to Sep 2026

Quarter to Sep 2026 · Consolidated · next results expected soon

Sales₹22.0 Crno comparison with Sep 2025
Operating profit₹6.00 Crno comparison with Sep 2025
Operating margin28.0%no comparison with Sep 2025
Net profit₹3.00 Crno comparison with Sep 2025
Net margin13.6%no comparison with Sep 2025
EPS₹2.93no comparison with Sep 2025
Sales, last 4 quarters ₹ crore
Show
Consolidated
Sales, operating profit and net profit, ₹ crore: 4 years to Mar 2026.
FY26Year to Mar 2026
Sales₹43.00 Cr
Operating profit₹20.00 Cr46% of sales
Net profit₹12.00 Cr27.9% of sales
Inside each sales bar: operating profit, and inside that, net profit.OPM: operating profit as % of sales. NPM: net profit as % of sales.

Years to March, 2023–2026 · key lines

Yearly profit and loss, Years to March, 2023–2026
LineMar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26
Sales₹ crore16.2315.25change on a year before -6%38.00change on a year before +149%43.00change on a year before +13%
Operating profit₹ crore1520change on a year before +33%
Operating margin% of sales10.47%36.93%40.00%46.00%
Net profit₹ crore0.332.50change on a year before +658%10.00change on a year before +300%12.00change on a year before +20%
EPS₹ per share0.362.72change on a year before +656%10.66change on a year before +292%12.95change on a year before +21%

Small figure: change on the year before. Lines that are 0 or blank in every column are not shown.

Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.

Sales

a year, compounded

3 years
38%
TTM
12%

Return on equity

average over the span

Last year
58%

3 · Quality & value

Answers

The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 38.4% a year against a sector median of 9.8% — 28.6 percentage points faster.

BMLL38.4% a year
Sector median9.8% a year

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

It has no steady three-year profit record yet, so growth cannot be weighed against the price.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 8 of 132 on returns, 5 of 132 on margin.

Returns on capital8 of 132
Margin5 of 132

A longer bar is a better rank.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 37.5% on capital, ahead of 94% of companies filed under the same label.

Return on capital37.5%
Ahead of94% of peers

Whether its growth pays for itself

Only 2 years of matching accounts on file — too few to judge this yet.

Peers here are the 132 companies the exchange files under the same label (Pharmaceuticals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Business score & profit checks

How strong the business is, and whether its profit is real cash. Facts only, not advice.

Business score

53 out of 100

How strong the business is, in one number. Last changed 20 Nov 2026.

How the business score works

Profit checks: is the profit real cash?

5 of 7 checks clear

2 of 9 checks could not be run.

Simple checks on the accounts. Which 2 are flagged is in Pro.

How the profit check works

PROHow the score was builtEach part of the score, with the numbers behind it
PROWhich checks were flaggedEvery check, the watch list and the filings behind them
PROFrom the filingsLoan defaults, and money lent or guaranteed to the promoters’ side
PROThe case for and againstA weighted list of what looks good and what looks weak

Key numbers & peers

Grouped by topic. Each number says what period it is for.

Price

Market cap
₹202 Cr
Prev close
₹160.70
52w High
₹181
52w Low
₹141
Beta
—
Price CAGR 1y
—
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Valuation

P/E ratioEPS FY to Mar 2026
17.0
Industry P/E
34.7
P/B ratio₹47 Cr IPO · by 27 May
Pending
EV / EBITDA₹47 Cr IPO · by 27 May
Pending
Enterprise value₹47 Cr IPO · by 27 May
Pending
PEG ratio
—
Dividend yield
0.0%

Returns

ROCE
37.5%
ROCE 5y average
37.5%
ROE
58.0%
ROE 3y average
—
ROE last year
58.0%
Return on assets
16.4%

Sales, profit & margins

Annual revenue
₹43.0 Cr
Annual profit
₹12.0 Cr
EPS
₹13.0
Operating margin
46.0%
Net profit margin
27.9%
EBITDA margin
46.5%
Sales latest quarterSep 2026 quarter
₹22.0 Cr
Profit latest quarterSep 2026 quarter
₹3.00 Cr
OPM latest quarterSep 2026 quarter
28.0%

Growth a year

Sales growth 3y
38.4%
Sales growth 5y
—
Sales growth TTM
12.0%
Profit growth 3y
—
Profit growth 5y
—
Profit growth TTM
—
YoY quarterly sales growth
—
YoY quarterly profit growth
—

Balance sheet

Book Value
Pending
Face Value
₹10.0
Borrowings
₹40.0 Cr
Total debt
₹33.0 Cr
Total cash
₹25.1 Cr
Debt / Equity
0.5
Interest coverage
9.0
Reserves / Equity
1.9

Cash & payout

Operating cash flow
-₹6.00 Cr
Free cash flow
-₹6.00 Cr
FCF yield
-4.0%
Net cash flow
₹0.00 Cr
Dividend payout
0.0%

Holdings

Promoter holding
67.7%
FII holding
4.8%
DII holding
3.6%
Public holding
23.9%

A newly listed company shows “Pending” until it files a balance sheet after its IPO: the last one is from before the issue, so the IPO money would be counted twice.

Peers

Peers
CompanyPrice ₹P/EMkt cap ₹ CrDiv yieldProfit qtr ₹ CrProfit changeSales qtr ₹ CrSales changeROCE
Sun Pharmaceutical1,884.9036.84,52,2440.86%1,995-36.16%16,199+11.88%20.60%
Divi's Laboratories11,180.5086.72,96,2830.27%1,127+63.57%3,676+35.40%21.97%
Torrent Pharmaceuticals4,689.5081.11,78,3700.82%534-9.64%4,979+50.79%19.56%
Laurus Labs Limited2,294.6092.51,23,9770.09%436+124.84%2,206+33.44%17.97%
Zydus Lifesciences1,200.0026.21,19,7600.08%928-25.13%7,910+29.17%22.69%
Dr Reddy's Laboratories1,390.2041.51,16,0820.58%913-31.70%8,698-1.48%13.75%
Cipla1,415.0036.81,14,3110.93%852-37.07%7,404-2.44%16.66%
Bio Medica Laboratories Limited160.7017.02020.00%3.0022.037.50%
Medianof the whole group of 129, 20 Nov 202634.90.09%+33.42%+19.60%15.01%

Median: the middle value of the whole peer group of 129 companies. Price and rupee sizes are left blank there, as a middle value of those says little.

Competes with 7 listed companies

Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

4 · Balance sheet & cash

Balance sheet

What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.

Consolidated

At Mar 2026: ₹73.0 cr of assets, and who funds them

Shareholders’ own money funds 36% of it; borrowings 55%.

What it owns

  • Fixed assets ₹17.0 cr 23%
  • Everything else ₹56.0 cr 77%

Who funds it

  • Shareholders’ money ₹26.0 cr 36%
  • Borrowings ₹40.0 cr 55%
  • Everything else ₹7.00 cr 10%

Each year end. Newest year end shaded.

Balance sheet
Line, ₹ croreMar 2025FY25Mar 2026FY26
Equity capital99
Reserves617
Borrowings1540
Other liabilities97
Total funding3973
Fixed assets817
Other assetsreceivables, cash, rest3156
Total assets3973

Cash flows

Real money coming in and going out — from the business, from investments and from loans. ₹ crore.

Consolidated

Pick a period to see where its cash went.

Where the cash went, year to Mar 2026, ₹ crore

In words

  • The business used ₹6.00 cr more than it brought in.
  • It put ₹2.00 cr into assets and investments.
  • It raised ₹8.00 cr from shareholders and lenders.
  • Cash in hand rose by ₹0.00 cr. Free cash flow: −₹6.00 cr.
Cash flow
Line, ₹ croreMar 2025FY25Mar 2026FY26
From the business-5-6
From investing0-2
From financingdividends, buybacks, loans58
Free cash flow-5-6
Cash ÷ operating profitbefore tax-33.00%-30.00%

Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.

Efficiency ratios

How fast customers pay and how well capital earns. Each year, Mar 2025 to Mar 2026.

Consolidated

Debtor days

92 days

Days customers take to pay. Lower is faster.

92 days in FY26, against 39 days in FY25. Over these 2 years: 39 days (FY25) to 92 days (FY26).

Inventory days

1338 days

Days stock sits before it is sold.

1338 days in FY26, against 678 days in FY25. Over these 2 years: 678 days (FY25) to 1338 days (FY26).

Days payable

205 days

Days it takes to pay its suppliers.

205 days in FY26, against 160 days in FY25. Over these 2 years: 160 days (FY25) to 205 days (FY26).

Cash conversion cycle

1225 days

Debtor days plus inventory days, less days payable.

1225 days in FY26, against 557 days in FY25. Over these 2 years: 557 days (FY25) to 1225 days (FY26).

Working capital days

300 days

Days of sales tied up in running the business.

300 days in FY26, against 166 days in FY25. Over these 2 years: 166 days (FY25) to 300 days (FY26).

5 · Owners & payouts

Shareholding pattern

Who owns the company: promoters, foreign funds, Indian funds and the public, at each quarter end. In %.

To 30 Sep 2026

Share of the company held by each group, at each filed quarter end, May 2026 to Sep 2026.

Promoters

The group that controls the company

67.70%

Since May 2026 no change

Foreign funds (FIIs)

Investors outside India

4.77%

Since May 2026 +4.48 pts

Indian funds (DIIs)

Mutual funds, insurers, banks

3.61%

Since May 2026 +1.30 pts

Public

Individuals and others

23.92%

Since May 2026 −5.79 pts

Number of shareholders

Accounts holding the share

331

Since May 2026 −864

  • Foreign funds raised their share from 0.29% to 4.77%; Indian funds raised theirs from 2.31% to 3.61%.
  • Promoters held 67.70% in every quarter from May 2026 to Sep 2026.
  • Shareholders fell from 1,195 to 331.
Shareholding, % of the company at each quarter end
Holder, %May 2026Sep 2026Change
Promoters67.7067.700.00
Foreign funds (FIIs)0.294.77+4.48
Indian funds (DIIs)2.313.61+1.30
Public29.7123.92−5.79
Shareholders1,195331−864

A figure in bold moved by 0.5 points or more from the quarter before. Change = Sep 2026 against May 2026, in points.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividend a share, by the year of its ex-date

No dividend on record.

Share of profit paid as dividend

No dividend payout is filed for this company.

Splits, bonuses & buybacks

None on record.

Big trades by funds and insiders

  • JAYANT BABULAL BOKADIAbulk deal, NSESold 80,000 · at ₹146.0027 Oct 2026
  • OSWAL ENERGIES LIMITEDbulk deal, NSEBought 80,000 · at ₹146.0027 Oct 2026
  • OSWAL ENERGIES LIMITEDbulk deal, NSEBought 1,44,000 · at ₹146.0026 Oct 2026
  • DIXIT JITENDRA BOKADIAbulk deal, NSESold 75,000 · at ₹146.0026 Oct 2026
  • RATAN BABULAL BOKADIAbulk deal, NSESold 69,000 · at ₹146.0026 Oct 2026
  • MAHABIR TRADEVENTURES LLPbulk deal, NSESold 1,18,000 · at ₹159.6019 Aug 2026
  • AGGARWAL ATUL KASTURILALbulk deal, NSEBought 1,16,000 · at ₹153.5018 Aug 2026
  • MAHABIR TRADEVENTURES LLPbulk deal, NSESold 1,16,000 · at ₹153.5018 Aug 2026
  • RATHOD MANOJ CHHAGANLAL HUFbulk deal, NSESold 91,000 · at ₹156.3618 Aug 2026
  • RATHOD MANOJ CHHAGANLAL HUFbulk deal, NSEBought 46,000 · at ₹156.3718 Aug 2026

The newest 10 of 40 on record.

6 · Price & trading

Open interestPRO

Where option traders are positioned on this stock.

7 · Business

About

What the company is, from our own records: where it sits, where its revenue comes from, and where it works.

Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BMLL
ISIN
INE1BKA01015
Part of
  • Nifty SME Emerge

Sites · 2

  • Unit No.1Indore, Madhya Pradesh
  • Unit No.2 (Registered Office)Indore, Madhya Pradesh

Industry numbers

The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.

Revenue and margin

  • EBIT marginSep 2026 quarter22.73%

Profit quality

  • Other income shareSep 2026 quarter20.00%
  • Interest coverMar 2026 quarter9.00x

Capex

  • CapexFY to Mar 2026₹0.00 Cr
  • Capex to revenueFY to Mar 20260.00%

How they have moved

EBIT margin · quarterly

Source: Computed from the filings

Sep 2622.73%Computed from the filings
Jun 26—not filed
Mar 2644.19%Computed from the filings

Other income share · quarterly

Source: Computed from the filings

Sep 2620.00%Computed from the filings
Jun 26—not filed
Mar 260.00%Computed from the filings

Capex (fiscal year) · yearly

Source: Computed from the filings

FY26₹0.00 CrComputed from the filings
FY25₹0.00 CrComputed from the filings

Capex to revenue (fiscal year) · yearly

Source: Computed from the filings

FY260.00%Computed from the filings
FY250.00%Computed from the filings

Supply chain

Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Bio Medica Laboratories Limited through this map.

Exports to · 1

  • Afghanistan

Competes with · 7 companies

Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.

8 · News & documents

News and what it reaches

Filings and news about Bio Medica Laboratories Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.

No recent news or filings for this company.

Documents

Earnings calls, results presentations and annual reports, straight from the company and the exchanges.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.